Factors influencing warfarin dose requirements in African-Americans.
about
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosingInfluence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsHigh-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African AmericansEstimation of the warfarin dose with clinical and pharmacogenetic data.A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.Warfarin dosing in patients with impaired kidney functionPractical Consideration of Genotype Imputation: Sample Size, Window Size, Reference Choice, and Untyped Rate.The future of warfarin pharmacogenetics in under-represented minority groups.Pharmacogenomics of warfarin in populations of African descent.Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.Role of pharmacogenomics in the management of traditional and novel oral anticoagulantsVKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-AmericansComparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town areaVKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot studyEthnic differences in warfarin maintenance dose requirement and its relationship with genetics.Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.Clinical applications of pharmacogenomics guided warfarin dosing.New oral anticoagulants: comparative pharmacology with vitamin K antagonists.Expanding role of pharmacogenomics in the management of cardiovascular disorders.Warfarin Pharmacogenomics in Diverse Populations.Personalized medicine: Genetic risk prediction of drug response.Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.Genetic and clinical predictors of warfarin dose requirements in African Americans.Shifting paradigms in the pharmacogenetics of warfarin.Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients
P2860
Q24641999-8D452701-DF8A-43E5-9E07-6D8ECE8E8FFBQ27002899-686843D2-914D-490E-908B-4689AD10359CQ28276514-1B8DC0C9-AFC3-4C9E-99E1-B464957C3086Q28395337-D54F4FB1-74AB-46C7-A304-5B7DD88BE674Q28740452-37B3DD01-3264-4956-856F-235DAC3866F2Q33410725-3EE0EF27-51F5-4870-A172-F93B5E3FF427Q34085379-08D75302-8EDE-42FE-95F4-E52826CA6BA7Q34238435-83AAFB08-1BD6-4730-86E9-0E66D2EDF3E0Q35720540-D123145B-B83F-422E-8455-CDF06FA5C6AAQ36294461-3BEEAEAA-89D1-45AE-8C75-F49693F49091Q36629209-932C5F40-B552-4A67-AC48-2856130D594BQ36651620-A88F409F-EA57-4820-B481-72334AA6E832Q36762797-D913D4A1-FC42-4E23-B50C-1772734F85E6Q36835168-AFC56BFC-6522-437E-915A-2F48673FFE7CQ36848449-6CA49CB9-808E-421B-B464-656BD35EC831Q36982736-08FB84B9-5509-4CD3-97A1-7CF112C0AA3AQ37077528-EFB5A83A-5173-4899-AB9C-B0545E73F09BQ37213180-99E70331-6BA8-4237-B149-79C75180503EQ37264555-932001DA-4479-429B-A3DC-5FF6D50946BAQ37376879-F792585C-EB7B-4E94-B477-60C6FE3B5035Q37807280-9E3E1ED4-A993-4A10-8201-5BB1A2207751Q38071973-70F36996-36CA-485D-8928-A8A25510561FQ38098452-5BE9E85D-328B-41E1-867F-FD92239FC860Q38696567-71C6AEAE-25ED-481F-834F-767E372AD390Q38756015-903EC6F9-3ED8-4634-BE34-0FFE3C64638AQ42718669-821309F8-08AA-431F-B6A8-ED0EEEB50384Q43195085-FDA448BD-5712-4050-8FBD-C5C17C12C56BQ46316268-43CF0375-6745-4C11-AF0A-986F3AB0AE9BQ46406579-CB129A23-3EC3-4981-9CB3-2972C9C0AA04Q46573199-EECF0DF4-3A8F-45FA-BFA3-665FA2132785Q47345423-EF887826-A1FD-4CA2-BFE1-64062E3F5D7FQ54966850-723AD516-33AA-4F37-AA95-47FA4A4A342DQ58558658-34D654A8-C22E-48E5-A6A8-BEC03028FFA7
P2860
Factors influencing warfarin dose requirements in African-Americans.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Factors influencing warfarin dose requirements in African-Americans.
@en
Factors influencing warfarin dose requirements in African-Americans.
@nl
type
label
Factors influencing warfarin dose requirements in African-Americans.
@en
Factors influencing warfarin dose requirements in African-Americans.
@nl
prefLabel
Factors influencing warfarin dose requirements in African-Americans.
@en
Factors influencing warfarin dose requirements in African-Americans.
@nl
P2093
P2860
P1433
P1476
Factors influencing warfarin dose requirements in African-Americans.
@en
P2093
Cathy M Helgason
Edith A Nutescu
Kathryn M Momary
Larisa H Cavallari
Marlos Ag Viana
Nancy L Shapiro
P2860
P304
P356
10.2217/14622416.8.11.1535
P577
2007-11-01T00:00:00Z